Differential modulation of glutamatergic transmission by 3,5-dibromo-L-phenylalanine

Molecular Pharmacology

Volumn 67, Issue 5, 2005, Pages 1648-1654

  Yarotskyy, V ^a   Glushakov, A V ^a   Sumners, C ^b   Gravenstein, N ^a,b   Dennis, D M ^a,b   Seubert, C N ^a   Martynyuk, Anatoly E ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 3,5 DIBROMOPHENYLALANINE; AMPA RECEPTOR; DIZOCILPINE; GLUTAMIC ACID; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENYLALANINE DERIVATIVE; UNCLASSIFIED DRUG;

AMPLITUDE MODULATION; ANIMAL CELL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; GLUTAMATERGIC TRANSMISSION; HYPOTHESIS; NERVE CELL CULTURE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NEWBORN; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STEADY STATE;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; PHENYLALANINE; RATS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 17844383689     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.005983     Document Type: Article

References (21)

1. Battaglia G, Monn JA, and Schoepp DD (1997) In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 229:161-164.
2. Cartmell J and Schoepp DD (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75:889-907.
3. Glushakov AV, Dennis DM, Morey TE, Sumners C, Cucchiara RF, Seubert CN, and Martynyuk AE (2002) Specific inhibition of N-methyl-D-aspartate receptor function in rat hippocampal neurons by L-phenylalanine at concentrations observed during phenylketonuria. Mol Psychiatry 7:359-367.
4. Glushakov AV, Dennis DM, Sumners C, Seubert CN, and Martynyuk AE (2003) L-Phenylalanine selectively depresses currents at glutamatergic excitatory synapses. J Neurosci Res 72:116-124.
5. Greene R (2001) Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro and psychosis of schizophrenia. Hippocampus 11:569-577.
6. Heresco-Levy U and Javitt DC (2004) Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 66:89-96.
7. Hirsch SR and Weinberger D (2003) Schizophrenia, Blackwell Publishing, Oxford, UK.
8. Hyman SE and Fenton WS (2003) Medicine. What are the right targets for psychopharmacology? Science (Wash DC) 299:350-351.
9. Jentsch JD and Roth RH (1999) The neuropsychophamacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
10. Kagiyama T, Glushakov AV, Sumners C, Roose B, Dennis DM, Phillips MI, Ozcan MS, Seubert CN, and Martynyuk AE (2004) Neuroprotective action of halogenated derivatives of L-phenylalanine. Stroke 35:1192-1196.
11. Konradia C and Heckers S (2003) Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 97:153-179.
12. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
13. Laube B, Hirai H, Sturgess M, Betz H, and Kuhse J (1997) Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 18:493-503.
14. Lipska BK and Weinberger DR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23:223-239.
15. Lorrain DS, Baccei CS, Bristow LJ, Anderaon JJ, and Varney MA (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117:697-706.
16. Meador-Woodruff JH and Healy DJ (2000) Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 31:288-294.
17. Moghaddam B (2003) Bringing order to the glutamate chaos in schizophrenia. Neuron 40:881-884.
18. Moghaddam B and Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (Wash DC) 281:1349-1352.
19. Moghaddam B, Adams B, Verma A, and Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Neuroscience 17:2921-2927.
20. Moghaddam B and Jackson ME (2003) Glutamatergic animal models of schizophrenia. Ann NY Acad Sci 1003:131-137.
21. Takahata R and Moghaddam B (2003) Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 28:1117-1124.